Clinical Trial Update: A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bempegaldesleukin (BEMPEG) plus nivolumab versus investigator's choice TKI therapy in advanced/metastatic renal cell carcinoma; trial t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)
• bempegaldesleukin (NKTR-214) (bempegaldesleukin)
• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2023-04-11